Sharma_2024_RSC.Adv_14_26703

Reference

Title : Design, synthesis, in silico, and in vitro evaluation of pyrrol-2-yl-phenyl allylidene hydrazine carboximidamide derivatives as AChE\/BACE 1 dual inhibitors - Sharma_2024_RSC.Adv_14_26703
Author(s) : Sharma A , Rudrawar S , Bharate SB , Jadhav HR
Ref : RSC Adv , 14 :26703 , 2024
Abstract :

Alzheimer's disease (AD) manifests as a progressive decline in cognitive function and mental behavior. Targeting two crucial enzymes associated with AD, acetylcholinesterase (AChE) and BACE 1 (Beta-site APP Cleaving Enzyme), in combination, holds promise for therapeutic breakthroughs. In this study, 40 derivatives of pyrrol-2-yl-phenyl allylidene hydrazine carboximidamide were designed based on prior research. These derivatives underwent synthesis and assessment for their inhibitory potential against AChE and BACE 1. ADME predictions indicated favorable physicochemical properties for these compounds. The findings offer novel avenues for exploring the dual inhibition of AChE and BACE 1 as a promising therapeutic strategy for AD.

PubMedSearch : Sharma_2024_RSC.Adv_14_26703
PubMedID: 39184009

Related information

Citations formats

Sharma A, Rudrawar S, Bharate SB, Jadhav HR (2024)
Design, synthesis, in silico, and in vitro evaluation of pyrrol-2-yl-phenyl allylidene hydrazine carboximidamide derivatives as AChE\/BACE 1 dual inhibitors
RSC Adv 14 :26703

Sharma A, Rudrawar S, Bharate SB, Jadhav HR (2024)
RSC Adv 14 :26703